Diabetes Management Guidelines
American Diabetes Association (ADA) 2013 Guidelines
Updated recommendations are available. Click here.
Source: American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(suppl 1):S11-S66.
Jump to a section or click the arrow at the bottom right of each section
Type 2 Diabetes Treatment :: Hyperglycemia Updated recommendations are available. Click here.
- Preferred initial therapy (if tolerated and not contraindicated)
- Consider insulin therapy
- With or without other agents at outset in newly diagnosed patients with markedly symptomatic and/or elevated blood glucose levels or A1C
- Add second oral agent, GLP-1 receptor agonist, or insulin
- If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain A1C target over 3–6 months
- Choice of pharmacologic therapy should be based on a patient-centered approach
- Potential side effects
- Effects on weight
- Hypoglycemia risk
- Patient preferences
- Insulin therapy is eventually needed for many patients due to progressive nature of type 2 diabetes
ADA Guidelines: Pharmacologic Therapy for Hyperglycemia in Type 2 Diabetes (1 of 2)
ADA Guidelines: Pharmacologic Therapy for Hyperglycemia in Type 2 Diabetes (2 of 2)
The pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual package inserts for use outside of the United States.
This content was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.